|本期目录/Table of Contents|

[1]顾 梅,徐华诚*,段帅凯,等.替诺福韦合成工艺的优化及抗菌活性研究[J].武汉工程大学学报,2024,46(01):18-26.[doi:10.19843/j.cnki.CN42-1779/TQ. 202209016]
 GU Mei,XU Huacheng*,DUAN Shuaikai,et al.Synthesis optimization and antibacterial activities of tenofovir[J].Journal of Wuhan Institute of Technology,2024,46(01):18-26.[doi:10.19843/j.cnki.CN42-1779/TQ. 202209016]
点击复制

替诺福韦合成工艺的优化及抗菌活性研究(/HTML)
分享到:

《武汉工程大学学报》[ISSN:1674-2869/CN:42-1779/TQ]

卷:
46
期数:
2024年01期
页码:
18-26
栏目:
化学与化学工程
出版日期:
2024-03-12

文章信息/Info

Title:
Synthesis optimization and antibacterial activities of tenofovir
文章编号:
1674 - 2869(2024)01 - 0018 - 09
作者:
顾 梅1徐华诚*2段帅凯3陈连清3李泉丹1习本军4
1. 北大医药股份有限公司,重庆 401121;
2. 福安药业集团重庆礼邦药物开发有限公司,重庆 401121;
3. 中南民族大学化学与材料科学学院,湖北 武汉 430074
4. 湖北三峡实验室,湖北 宜昌 443007
Author(s):
GU Mei1 XU Huacheng*2 DUAN Shuaikai3 CHEN Lianqing3 LI Quandan1 XI Benjun4
1. PKU Health Care Corp., Ltd., Chongqing 401121, China;
2. Fu’an Pharmaceutical Group Chongqing LYBON Pharm-Tech. Co., Ltd, Chongqing 401121, China;
3. College of Chemistry and Materials Science, South-Central MinZu University, Wuhan 430074, China;
4. Hubei Three Gorges Laboratory, Yichang 443007, China
关键词:
替诺福韦高效液相色谱法中控荧光监测工艺优化抗菌活性
Keywords:
tenofovir HPLC central control fluorescence monitoring process optimization antibacterial activity
分类号:
TB383
DOI:
10.19843/j.cnki.CN42-1779/TQ. 202209016
文献标志码:
A
摘要:
为了优化替诺福韦合成工艺,以腺嘌呤和(R)-碳酸丙烯酯为起始原料,经开环缩合、取代、水解得到替诺福韦。通过高效液相色谱法(HPLC)监控整个反应过程,其中开环缩合的最佳反应条件为反应温度120 ℃,反应时间22 h;取代的最佳反应条件为反应温度60 ℃,反应时间6 h;水解的最佳反应时间20 h。在最优化条件下总收率达69.2%。通过紫外-可见吸收光谱和荧光发射光谱探讨其光物理性能,发现可以根据不同化合物的荧光发射波长差异来监测反应方向和反应程度;通过抗菌活性测试,发现对低浓度的金黄色葡萄球菌有一定的抗菌活性。该合成工艺实现了副产物回收套用,节约生产成本,提高产能。

Abstract:
To optimize the synthetic process of tenofovir, we synthesized tenofovir using adenine and (R)-propylene carbonate as starting materials through ring-opening condensation, substitution and hydrolysis. The processes of reactions were monitored by using high performance liquid chromatography. The best synthesis conditions for ring-opening condensation and substitution reaction were at 120 ℃ for 22 h and at 60 ℃ for 6 h, respectively. The best reaction time of hydrolysis is 20 h. The total yield is 69.2% under optimal conditions. The photophysical properties were investigated by UV-vis absorption spectroscopy and fluorescence emission spectroscopy, and the direction and extent of reaction can be monitored according to the wavelengths of fluorescence emission of different compounds. Tenofovir shows certain antibacterial activities against Staphylococcus aureus at a low concentration. This synthetic process realizes the by-product recovery and application, saves the production cost, and improves the production capacity.

参考文献/References:

[1] LI B J, LIU Z Z, LIU X, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load [J]. Hepatology International, 2021, 15(5): 1103-1108.

[2] QURESHI A, OUATTARA L A, EISAYED N S, et al. Synthesis and evaluation of anti-HIV activity of mono- and di-substituted phosphonamidate conjugates of tenofovir [J]. Molecules, 2022, 27(14): 4447.
[3] SEVENLER D, BARDON A, FERNANDEZ S M, et al. Immunoassay for HIV drug metabolites tenofovir and tenofovir diphosphate [J]. ACS Infectious Diseases, 2020, 6(7): 1635-1642.
[4] TSENG C H, HSU Y C, CHEN T H, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis[J]. The Lancet Gastroenterology and Hepatology,2020,5(12): 1039-1052.
[5] LIM J, CHOI W M, SHIM J H, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-na?ve chronic hepatitis B [J]. Liver International, 2022, 42(7): 1517-1527.
[6] LI Y P, YANG B, QUAN Y N, et al. Advancement of prodrug approaches for nucleotide antiviral agents [J]. Current Topics in Medicinal Chemistry, 2021, 21(32): 2909-2927.
[7] KALCIC F, ZGARBOVA M, HODEK J, et al. Discovery of modified amidate (ProTide) prodrugs of tenofovir with enhanced antiviral properties [J]. Journal of Medicinal Chemistry, 2021, 64(50): 16425-16449.
[8] 尚胜捷, 王璨, 陈云峰. 抗病毒药物中间体替诺福韦的合成工艺研究 [J]. 武汉工程大学学报, 2022, 44(6): 619-623, 663.
[9] AMBLARD F, PATEL D, MICHAILIDIS E, et al. HIV nucleoside reverse transcriptase inhibitors [J]. European Journal of Medicinal Chemistry, 2022, 240: 114554.
[10] 张杰, 施务务, 葛少波, 等. 替诺福韦的合成工艺研究 [J]. 世界最新医学信息文摘, 2015, 15(50): 130.
[11] 王志刚, 聂静, 王治国. 泰诺福韦的合成工艺研究 [J]. 湖北理工学院学报, 2015, 31(5): 46-49.
[12] 刘嘉, 李科, 孙海玲, 等. 替诺福韦的合成工艺改进 [J]. 药学实践杂志, 2009, 27(1): 31-32.
[13] 李陈, 杨芳, 郭建琼, 等. 替诺福韦的合成工艺优化研究 [J]. 化学研究与应用, 2018, 30(6): 970-973.
[14] DIETZ J P, FERENC D, JAMISON T F, et al. Di-tert-butyl phosphonate route to the antiviral drug tenofovir [J]. Organic Process Research & Development, 2021, 25 (4): 789-798.
[15] ZHANG Q Q, PENG Y M, HOU J, et al. An O-benzyl phosphonamidate prodrug of tenofovir for the treatment of hepatitis B virus infection [J]. European Journal of Medicinal Chemistry, 2022, 65 (13): 9493-9505.
[16] RILEY D L, WALWYN D R, EDLIN C D. An improved process for preparation of tenofovir disoproxil fumarate [J]. Organic Process Research & Development, 2016, 20(4): 742-750.
[17] YOSHIDA Y, HONMA M, KIMURA Y, et al. Structure, synthesis and inhibition mechanism of nucleoside analogues as HIV‐1 reverse transcriptase inhibitors (NRTIs) [J]. Journal of Medicinal Chemistry, 2021, 16 (5): 743-766.
[18] YANG J T, LI Z, HU F F, et al. Synthesis of multimeric impurities of tenofovir disoproxil fumarate [J]. Organic Preparations and Procedures International, 2019, 51 (4): 397-402.
[19] DERSTINE B P, TOMLIN J W, PECK C L, et al. An efficient synthesis of tenofovir (PMPA): a key intermediate leading to tenofovir-based HIV medicines [J]. Organic Process Research & Development, 2020, 24?(8): 1420-1427.
[20] MANDALA D, THOMPSON W A, WATTS P. Synthesis routes to anti-HIV drugs [J]. Tetrahedron Letters, 2016, 72 (24): 3389-3420.
[21] SUVEGES N S, RODRIGUEZ A A, DIEDERICHS C C, et al. Continuous-flow synthesis of (R)-propylene carbonate: an important intermediate in the synthesis of tenofovir [J]. European Journal of Organic Chemistry, 2018, 2018 (23): 2931-2938.
[22] WANG A P, WU S, TAO Z Y, et al. Design, synthesis, and anti-HBV activity of new bis(L-amino acid) ester tenofovir prodrugs [J]. ACS Medicinal Chemistry Letters, 2019, 10 (6): 991-995.

相似文献/References:

备注/Memo

备注/Memo:
收稿日期:2022-09-13
基金项目:中央高校基本科研业务费专项资金项目(CXY22006、CZY23013);湖北三峡实验室开放/创新基金(SC232015)
作者简介:顾 梅,硕士,高级工程师。Email: [email protected]
*通信作者:徐华诚,硕士,工程师。Email: [email protected]
引文格式:顾梅,徐华诚,段帅凯,等. 替诺福韦合成工艺的优化及抗菌活性研究[J]. 武汉工程大学学报,2023,45(6):18-26.
更新日期/Last Update: 2024-03-01